archive-au.com » AU » C » CSL.COM.AU

Total: 502

Choose link from "Titles, links and description words view":

Or switch to "Titles and links view".
  • CSL Biotherapies awarded Pandemic Preparedness Contract by US Government
    the terms of the contract the US Government may request CSL Biotherapies to manufacture and store bulk antigen that can be used against influenza strains with pandemic potential The Company may also be called upon to develop working virus seeds for other manufacturers and to formulate fill and finish bulk stored antigen CSL Biotherapies is the only manufacturer of influenza vaccine in the Southern Hemisphere with a capacity to produce in excess of 80 million doses of vaccine per annum CSL Biotherapies is unique in that it is involved in every stage of influenza vaccine manufacture from the development of the seed viruses necessary to produce vaccine all the way through to final packaged product in syringes ready to be administered During the 2009 H1N1 pandemic CSL Biotherapies was pivotal in producing vaccine early initiating world first clinical trials and providing pandemic vaccine for vaccination programs in Australia New Zealand the United States Germany Singapore and Canada as well as to the World Health Organisation CSL Biotherapies has a long and proud history of developing and manufacturing vaccines dating back to the 1918 Spanish Flu pandemic said Dr John Anderson General Manager of CSL Biotherapies Influenza pandemics can have devastating impacts and we are very pleased to be working with the US Government in their pandemic preparedness efforts As Australia s only on shore influenza vaccine manufacturer CSL Biotherapies is already contracted by the Commonwealth Government to manufacture vaccines in the event of an influenza pandemic CSL takes its role in protecting Australia against pandemic influenza very seriously and we continually invest in our operations to remain pandemic ready said Dr Anderson This puts us in a strong position to collaborate with governments globally to prepare for a pandemic emergency Funding for the CSL Biotherapies contract is provided solely by

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1196562649899/news/1255929640961/prdetail.htm (2014-01-05)
    Open archived version from archive


  • CSL Limited today announced Full Year Results for 2011/12.
    months ended 30 June 2012 up A 42 million or 4 5 on a reported basis when compared to the prior comparable period This result included an unfavourable foreign exchange impact of A 108 million On a constant currency 1 basis net profit after tax grew 16 Earnings per share growth continues to benefit from current and past capital management initiatives Download this release ASX Full Year Information 0 15

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1196562649899/news/1255929472428/prdetail.htm (2014-01-05)
    Open archived version from archive

  • Successor to CEO Brian McNamee Announced
    of CEO strong leadership qualities and more than 30 years experience in the healthcare and biopharmaceutical industry Professor Shine said that long term succession planning for Dr McNamee had been underway for some time He said This plan is in line with our market announcement in December 2009 that Brian would continue as CEO for three to four years He said he was very pleased that the Board had been able to select a candidate of Mr Perreault s stature and capability from current management Paul was selected after consideration of a strong field of well qualified candidates The process has reconfirmed the Board s confidence in the quality and depth of CSL s global management Paul brings tremendous leadership capability to the role together with deep experience in the day to day management of CSL s global operations He has been closely involved in the development of the current strategy and we are confident he will continue the trajectory of CSL s growth and outstanding performance Professor Shine said Professor Shine said that he was pleased that Dr McNamee would continue to lead the organisation through until June 2013 Brian will run the business as normal giving us the continued benefit of his leadership right up to the hand over mid next year he said He said that both Brian and the Board felt the time was right to pass the baton to the next leadership of the Company and he wanted to acknowledge Brian s extraordinary contribution both to CSL and the local and international pharmaceutical industry Brian s achievement is the CSL you see today He and his talented team many of whom remain part of the leadership built it more or less from scratch When Brian took over in 1990 CSL was a domestic focussed government

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1196562649899/news/1255929393054/prdetail.htm (2014-01-05)
    Open archived version from archive

  • Retirement of Director - Peter Turner
    Turner an Executive Director of CSL will be leaving the Company as an executive and as a consequence retiring as a director of CSL as of 17 October 2012 Mr Turner has been a director of CSL since December 2009 and has had a long and distinguished career with CSL for over 45 years Professor John Shine CSL s Chairman said Peter has made an invaluable contribution to CSL over

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1196562649899/news/1255929304751/prdetail.htm (2014-01-05)
    Open archived version from archive

  • Half-year results announcement for 2011/12
    ended 31 December 2011 down 17 million or 3 on a reported basis when compared to the prior comparable period This result included an unfavourable foreign exchange impact of 95 million On a constant currency 1 basis net profit after tax grew 16 Earnings per share benefited from current and past capital management initiatives Download this release CSL Half Year Results Announcement for 2011 12 0 08 Mb Additional resources

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1196562649899/news/1255928307673/prdetail.htm (2014-01-05)
    Open archived version from archive

  • CSL Biotherapies provides update on Fluvax® investigation
    associated with a higher rate of fever in children compared to at least one other licensed influenza vaccine but that Fluvax had not been previously linked to a significant risk of febrile convulsion 2 3 CSL s extensive manufacturing investigations which reviewed all aspects of the manufacturing process from starting materials through to finished product did not identify any raw material issues process changes or deviations from the CSL standard method of manufacture that explained the increased adverse reactions in children in 2010 CSL s preliminary conclusion is that its standard method of manufacture retains more virus components than that of other manufacturers and that the particular characteristics of the 2010 virus components elicited an excessive immune response in some young children triggering increased fever and fever related convulsions Dr Darryl Maher Vice President of Medical and Research at CSL Biotherapies says While influenza vaccines must contain virus components to stimulate sufficient protection against influenza it appears that components of the inactivated virus retained in Fluvax in 2010 overstimulated the developing immune systems of some young children compared to previous seasons The preliminary conclusion is underpinned by comprehensive scientific studies into the virus disruption splitting process of CSL s method of manufacture CSL has found in laboratory experiments that increasing the amount of splitting agent used can reduce the amount of reactive virus components in Fluvax CSL is undertaking ongoing studies to understand how the characteristics of the reactive virus components in Fluvax contributed to the adverse events in children in 2010 and to further investigate process changes that will adequately reduce them It will take some time to complete this work and to fully evaluate the impact and acceptability of any process modifications made It is important that such changes not only make Fluvax safe and effective for children but that they also retain the current protective benefits of Fluvax for adults and the elderly The investigations have been complex because of the multiple biological factors involved There is more work to do but we have made substantial progress in both isolating the cause of the adverse events and identifying potential process changes that will prevent them from happening again says Dr Maher Until these further studies are completed and both CSL and the regulators are fully confident that our manufacturing process can consistently produce a safe and effective influenza vaccine for children we will continue to fully support the age restrictions currently in place for children in all markets says Dr Maher Fluvax is not licensed for use in children aged under 5 years and is only recommended for at risk children aged between 5 and 9 years if no other licensed influenza vaccine is available A recent review conducted by the Australian Technical Advisory Group on Immunisation ATAGI found that Fluvax continues to have an acceptable safety profile in people aged 10 years and over This is consistent with previous published clinical studies and CSL s ongoing global safety monitoring 4 5 6 Influenza is a serious

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1255929043091/news/1255929042869/prdetail.htm (2014-01-05)
    Open archived version from archive

  • Search Results
    REPORT 2011 2012 CSL Limited ABN 99 051 588 348 Annual Report 2011 2012 Financial calendar 2013 20 February Half year profit and interim dividend announcement 13 http www csl com au docs 494 678 csl ar 2012 0 pdf CSL Limited CSL Limited Annual Report 2010 2011 CSL Limited ABN 99 051 588 348 Annual Report 2010 2011 Annual General Meeting Wednesday 19 October 2011 at 10 00am Function Centre National http www csl com au docs 621 800 csl ar 2011 0 pdf untitled CSL LIMITED ANNUAL REPORT 2008 2009 CSL Limited ABN 99 051 588 348 Annual Report 2008 2009 YEAR IN REVIEW 1 Highlights 2 Financial Results 3 Year in Review BUSINESS FEATURES 8 CSL http www csl com au docs 470 537 csl ar 2009 pdf CSL Limited Annual Report CSL Limited Annual Report 2006 2007 CSL Limited ABN 99 051 588 348 Annual Report 2006 2007 Year in Review 1 Highlights 2 Financial Results 3 Year in Review Business Features 8 CSL http www csl com au docs 692 27 CSL AR 2007 pdf CSL Limited Our Corporate Responsibility CSL Limited Our Corporate Responsibility 2009 CSL Limited ABN 99 051 588 348 Our Corporate Responsibility 2009 Emily Bartko Emily Bartko celebrated her third birthday by having her http www csl com au docs 651 1009 CSL CSR 2009 pdf CSL LIMITED OUR CORPORATE RESPONSIBILITY CSL LIMITED OUR CORPORATE RESPONSIBILITY 2010 Contents 1 OUR ORGANISATION 04 1 1 Report of our manufacturing sites 39 7 4 CSL Plasma 44 7 5 Environmental reporting and http www csl com au 556 CSL CR Report 2010 Internet pdf CSL Limited CSL Limited our Corporate reSponSibiLity 2013 ContentS Next page CSL Limited aBN 99 051 588 348 our Corporate responsibility 2013 3 1 performance 14 3 2 Safety

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1255924054987/page/1255924054283/SearchResults.htm?query=csl&pr=CSLsites&prox=page&rorder=500&rprox=500&rdfreq=500&rwfreq=500&rlead=500&rdepth=0&sufs=0&order=r&cq=2&jump=0&dropXSL=yes (2014-01-05)
    Open archived version from archive

  • Search Results
    com au 230 news 1255929393054 prdetail htm Archived ASX Releases 2008 2012 Global Home CSL Behring Global bioCSL All CSL Websites CSL Include All CSL Behring Country Sites Choose country Austria Belgium Luxembourg Brazil Canada China Denmark France http www csl com au 55928308342 PressReleaseArchive htm CSL Support of Australian Patient Groups Global Home CSL Behring Global bioCSL All CSL Websites CSL Include All CSL Behring Country Sites Choose country Austria Belgium Luxembourg Brazil Canada China Denmark France http www csl com au 8 content 1255924873702 content htm Microsoft Word ASX USD Historical Financials v4 Final For immediate release 23 October 2012 CSL Historical Financial Performance in US Dollars preparation of CSL Limited s audited consolidated financial statements for these periods http www csl com au docs 1013 277 1159445 pdf News Archive Global Home CSL Behring Global bioCSL All CSL Websites CSL Include All CSL Behring Country Sites Choose country Austria Belgium Luxembourg Brazil Canada China Denmark France http www csl com au 899 news 1196562739532 prdetail htm News Archive Global Home CSL Behring Global bioCSL All CSL Websites CSL Include All CSL Behring Country Sites Choose country Austria Belgium Luxembourg Brazil Canada China Denmark France http www csl com au 899 news 1196562740511 prdetail htm CSL Biotherapies Statement on FDA Warning Letter for GMP issues Global Home CSL Behring Global bioCSL All CSL Websites CSL Include All CSL Behring Country Sites Choose country Austria Belgium Luxembourg Brazil Canada China Denmark France http www csl com au 899 news 1255926584811 prdetail htm CSL Announces Changes to the Board Global Home CSL Behring Global bioCSL All CSL Websites CSL Include All CSL Behring Country Sites Choose country Austria Belgium Luxembourg Brazil Canada China Denmark France http www csl com au 899 news 1255927066426 prdetail htm CSL Limited today announced CSL

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1255924054987/page/1255924054283/SearchResults.htm?query=csl&pr=CSLsites&prox=page&rorder=500&rprox=500&rdfreq=500&rwfreq=500&rlead=500&rdepth=0&sufs=0&order=r&cq=2&jump=100&dropXSL=yes (2014-01-05)
    Open archived version from archive